Precision Medicine Is Precisely Right Theme For Biopharma: Impact Of Therapy—Not Cost—Is Focus
This article was originally published in RPM Report
Executive Summary
A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.